Today we’re excited to announce a new collaboration with UCB, a multinational biopharma company headquartered in Brussels, Belgium, with the launch of a digital health trial for myasthenia gravis, a neuromuscular disease that can lead to impaired speech, blurred vision, difficulty swallowing, and other symptoms.
Welcome to our blog
Digital health studies
Coronavirus, pandemic and COVID-19 are still relatively new additions to our daily vocabularies. We now live in a world that seems much slower, full of constant browser refreshes for updates, nostalgia for the way things were, and carefully planned outings to the grocery store. Yet, a competitive race is underway, as our futures are now tied to the breakthroughs made by medical researchers, and importantly, to the people participating in clinical trials.
Tracked individualized reports are now available at the end of the trial in the doc.ai app. Medical research can feel like a black box when you enroll in clinical studies. Why? Because you share your data and personal information for months without any access to it or even the possibility to share it with your healthcare provider. It doesn’t have to be that way anymore.
doc.ai has seen awesome demand for a new kind of prospective research study called a data trial. Our first data trial was launched this past fall and called “Can Artificial Intelligence Predict Your Risk of Allergies?”